A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration

John W Kitchens,1,* Nawal Kassem,2,* William Wood,1 Thomas W Stone,1 Rick Isernhagen,1 Edward Wood,1 Brad A Hancock,2 Milan Radovich,2,4 Josh Waymire,4 Lang Li,3,4 Bryan P Schneider2,41Ophthalmology, Retina Associates of Kentucky, Lexington, KY; 2Department of Medicine, Divisions of Hematology/Oncol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kitchens JW, Kassem N, Wood W, Stone TW, Isernhagen R, Wood E, Hancock BA, Radovich M, Waymire J, Li L, Schneider BP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a74d4a465efe434faf1d47ab8ba895cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a74d4a465efe434faf1d47ab8ba895cc
record_format	dspace
spelling	oai:doaj.org-article:a74d4a465efe434faf1d47ab8ba895cc2021-12-02T00:34:49ZA pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration1177-54671177-5483https://doaj.org/article/a74d4a465efe434faf1d47ab8ba895cc2013-10-01T00:00:00Zhttp://www.dovepress.com/a-pharmacogenetics-study-to-predict-outcome-in-patients-receiving-anti-a14635https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483John W Kitchens,1,* Nawal Kassem,2,* William Wood,1 Thomas W Stone,1 Rick Isernhagen,1 Edward Wood,1 Brad A Hancock,2 Milan Radovich,2,4 Josh Waymire,4 Lang Li,3,4 Bryan P Schneider2,41Ophthalmology, Retina Associates of Kentucky, Lexington, KY; 2Department of Medicine, Divisions of Hematology/Oncology, 3Biostatistics, 4Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA *These authors contributed equallyPurpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD).Methods: Patients with “wet” AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes.Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT.Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.Keywords: age related macular degeneration, ARMS2, bevacizumab, complement factor H (CFH), LOC387715, ranibizumab, single nucleotide polymorphisms, vascular endothelial growth factorKitchens JWKassem NWood WStone TWIsernhagen RWood EHancock BARadovich MWaymire JLi LSchneider BPDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 1987-1993 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Kitchens JW Kassem N Wood W Stone TW Isernhagen R Wood E Hancock BA Radovich M Waymire J Li L Schneider BP A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
description	John W Kitchens,1,* Nawal Kassem,2,* William Wood,1 Thomas W Stone,1 Rick Isernhagen,1 Edward Wood,1 Brad A Hancock,2 Milan Radovich,2,4 Josh Waymire,4 Lang Li,3,4 Bryan P Schneider2,41Ophthalmology, Retina Associates of Kentucky, Lexington, KY; 2Department of Medicine, Divisions of Hematology/Oncology, 3Biostatistics, 4Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA *These authors contributed equallyPurpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD).Methods: Patients with “wet” AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes.Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT.Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.Keywords: age related macular degeneration, ARMS2, bevacizumab, complement factor H (CFH), LOC387715, ranibizumab, single nucleotide polymorphisms, vascular endothelial growth factor
format	article
author	Kitchens JW Kassem N Wood W Stone TW Isernhagen R Wood E Hancock BA Radovich M Waymire J Li L Schneider BP
author_facet	Kitchens JW Kassem N Wood W Stone TW Isernhagen R Wood E Hancock BA Radovich M Waymire J Li L Schneider BP
author_sort	Kitchens JW
title	A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
title_short	A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
title_full	A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
title_fullStr	A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
title_full_unstemmed	A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
title_sort	pharmacogenetics study to predict outcome in patients receiving anti-vegf therapy in age related macular degeneration
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/a74d4a465efe434faf1d47ab8ba895cc
work_keys_str_mv	AT kitchensjw apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT kassemn apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT woodw apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT stonetw apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT isernhagenr apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT woode apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT hancockba apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT radovichm apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT waymirej apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT lil apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT schneiderbp apharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT kitchensjw pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT kassemn pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT woodw pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT stonetw pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT isernhagenr pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT woode pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT hancockba pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT radovichm pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT waymirej pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT lil pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration AT schneiderbp pharmacogeneticsstudytopredictoutcomeinpatientsreceivingantivegftherapyinagerelatedmaculardegeneration
_version_	1718403638209019904

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration

Ejemplares similares